September 30, 2020
Business News

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs


UTRECHT, The Netherlands & PHILADELPHIA–()–LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 million (€71 million) Series C financing to fund the advancement of its pipeline and platform. The financing was co-led by new investors Novo Ventures, the venture arm of Novo Holdings, and Sanofi Ventures, and included additional new investors Redmile Group, LLC, Ysios Capital and BB Pureos Bioventures. In addition, current investors Versant, Gilde Healthcare and MRL Ventures Fund, LLC participated significantly in the round.

As part of the transaction, Nanna Lüneborg,…



Click here to view the original article.

Related Posts

You might also like ...

Cintas Celebrates 2020 Custodian of the Year Winner in Albertville
AON Splash Image
Clearday Announces Expected Continuation of the Merger Agreement With Superconductor Technologies Inc.
Comcast Invests in Growth and Technology Infrastructure